Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
2.930
-0.150 (-4.87%)
Oct 30, 2026, 4:00 PM EDT - Market closed
Evaxion Employees
Evaxion had 46 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Evaxion the 35,386th largest employer in the world and 4,757th in the United States.
Employees
46
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$162,848
Profits / Employee
-$188,152
Market Cap
24.44M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 46 | 0 | - |
| Dec 31, 2024 | 46 | -3 | -6.12% |
| Dec 31, 2023 | 49 | -14 | -22.22% |
| Dec 31, 2022 | 63 | 2 | 3.28% |
| Dec 31, 2021 | 61 | 26 | 74.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| BeyondSpring | 44 |
| ABVC BioPharma | 19 |
| BriaCell Therapeutics | 16 |
| Atossa Therapeutics | 16 |
| CervoMed | 15 |
| TransCode Therapeutics | 12 |
| Quoin Pharmaceuticals | 6 |
EVAX News
- 1 day ago - Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution - GlobeNewsWire
- 2 days ago - Evaxion Transcript: Study update - Transcripts
- 2 days ago - Evaxion Slides: Study update - Filings
- 8 days ago - Evaxion Biotech presents three-year immune and clinical outcome data for EVX-01 - TheFly
- 9 days ago - Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 - GlobeNewsWire
- 10 days ago - Evaxion Slides: Corporate presentation - Filings
- 12 days ago - Evaxion Biotech reports three-year clinical outcome data for EVX-01 - TheFly
- 13 days ago - Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 - GlobeNewsWire